NeuroPace Inc.

10.78
0.35 (3.36%)
At close: Apr 17, 2025, 3:59 PM
10.09
-6.43%
After-hours: Apr 17, 2025, 07:59 PM EDT
3.36%
Bid 7.73
Market Cap 351M
Revenue (ttm) 79.91M
Net Income (ttm) -27.14M
EPS (ttm) -0.93
PE Ratio (ttm) -11.59
Forward PE -17.67
Analyst Buy
Ask 10.75
Volume 145,096
Avg. Volume (20D) 251,696
Open 10.51
Previous Close 10.43
Day's Range 10.32 - 10.88
52-Week Range 5.45 - 15.11
Beta 2.04

About NPCE

NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilitie...

Sector Healthcare
IPO Date Apr 22, 2021
Employees 184
Stock Exchange NASDAQ
Ticker Symbol NPCE
Full Company Profile

Analyst Forecast

According to 5 analyst ratings, the average rating for NPCE stock is "Buy." The 12-month stock price forecast is $17, which is an increase of 57.70% from the latest price.

Stock Forecasts

Next Earnings Release

NeuroPace Inc. is scheduled to release its earnings on May 13, 2025, after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
+9.11%
Neurospace shares are trading higher after UBS ini... Unlock content with Pro Subscription
5 months ago
+28.15%
Neuropace shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY24 sales guidance. Wells Fargo maintained an Overweight rating on the stock.